Virtus ETF Advisers LLC Has $74,000 Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Virtus ETF Advisers LLC lessened its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 82.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,707 shares of the company's stock after selling 8,064 shares during the period. Virtus ETF Advisers LLC's holdings in Scholar Rock were worth $74,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC lifted its position in shares of Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock valued at $34,000 after acquiring an additional 269 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock valued at $310,000 after purchasing an additional 379 shares during the period. Amalgamated Bank lifted its holdings in shares of Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after purchasing an additional 620 shares in the last quarter. Global Retirement Partners LLC boosted its position in shares of Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after buying an additional 766 shares during the period. Finally, Nisa Investment Advisors LLC grew its holdings in shares of Scholar Rock by 1,321.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after buying an additional 1,031 shares in the last quarter. 91.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Wedbush reissued an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $42.67.

Scholar Rock Stock Up 0.5 %

SRRK stock traded up $0.15 during mid-day trading on Friday, hitting $32.91. The stock had a trading volume of 1,339,190 shares, compared to its average volume of 1,256,493. The stock has a market capitalization of $3.12 billion, a price-to-earnings ratio of -14.00 and a beta of 0.56. The company has a fifty day moving average of $32.33 and a 200 day moving average of $35.75. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 1-year low of $6.76 and a 1-year high of $46.98.

Insider Transactions at Scholar Rock

In related news, CFO Edward H. Myles sold 7,809 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total value of $287,605.47. Following the completion of the sale, the chief financial officer now directly owns 140,740 shares in the company, valued at approximately $5,183,454.20. The trade was a 5.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mo Qatanani sold 68,510 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total value of $2,562,274.00. Following the transaction, the insider now owns 111,084 shares in the company, valued at approximately $4,154,541.60. This trade represents a 38.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 255,231 shares of company stock worth $9,220,236 in the last 90 days. 13.30% of the stock is owned by insiders.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.